Saturday 17 October 2026
Export ETON’s income statement to Excel — free account
Eton Pharmaceuticals, Inc.
ETON Healthcare Drug Manufacturers Specialty & Generic
Eton Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.0 million, up 104.9% from fiscal 2024. In the quarter to June 2026, revenue grew 98.6%, EPS grew 520.0%, free cash flow fell 8.78% and total debt fell 7.54%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
50.40
0.93
−1.81%
Follow ETON
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
77.02 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
9.48 | 7.75 | 5.69 | 8.31 | |
P/FCF ratio |
0.00 | 0.00 | 220.99 | 45.32 | |
P/Operating CF |
137.92 | 90.94 | (39.39) | 48.59 | |
P/B ratio |
21.48 | 22.00 | 17.40 | 25.27 | |
Price to Tangible BV |
1,103.24 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
9.49 | 7.87 | 5.75 | 8.21 | |
EV/EBITDA |
46.63 | 101.83 | 117.97 | 255.25 | |
EV/Operating CF |
66.18 | 43.21 | 43.67 | 27.11 | |
EV/FCF |
(119.42) | (88.88) | 223.23 | 44.80 | |
Quick Ratio |
1.15 | 0.75 | 0.98 | 1.14 | |
Current Ratio |
1.52 | 1.21 | 1.57 | 1.63 | |
Net Debt/EBITDA |
0.07 | 3.03 | 1.26 | 38.59 | |
Debt/Assets |
24.09% | 31.47% | 33.17% | 29.06% | |
Debt/Equity |
0.60 | 1.00 | 1.17 | 1.31 | |
Asset Turnover |
0.97 | 0.96 | 0.95 | 1.00 | |
Operating CF/Net income |
0.63 | 4.77 | (7.79) | (6.24) | |
Capex/Depreciation |
0.00 | (12.07) | (0.04) | (0.24) | |
Interest Coverage |
11.89 | 2.87 | — | (2.30) | |
Research and Development Expense of Revenue |
2.64% | 7.73% | 8.36% | 4.95% | |
Selling, General and Administrative Expense of Revenue |
30.93% | 43.05% | 41.61% | 36.09% | |
Intangible Assets out of Total Assets |
0.39 | 0.45 | 0.34 | 0.31 | |
Share Based Compensation of Revenue |
3.91% | 6.26% | 5.28% | 4.86% | |
Graham Net Nets |
0.00 | (0.02) | (0.01) | (0.02) | |
Graham Number |
4.22 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
1.30% | (0.20%) | (1.01%) | (1.15%) | |
Free Cash Flow Yield |
(0.84%) | (1.14%) | 0.45% | 2.21% | |
Revenue per Share |
1.36 | 0.89 | 0.79 | 0.84 | |
Operating CF per Share |
0.26 | 0.27 | (0.43) | 0.45 | |
Capex per Share |
0.00 | (0.55) | 0.00 | (0.01) | |
Free Cash Flow per Share |
0.26 | (0.28) | (0.43) | 0.44 | |
Cash per Share |
0.97 | 0.72 | 0.96 | 1.38 | |
Shareholders Equity per Share |
1.69 | 1.12 | 0.97 | 0.86 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.69 | 1.12 | 0.97 | 0.86 | |
Free Cash Flow |
7.26 | (7.67) | (11.60) | 11.74 | |
Working Capital |
23.48 | 9.07 | 22.09 | 27.82 | |
Capital Expenditures |
0.01 | (15.07) | (0.05) | (0.28) | |
Net Current Asset Value |
(0.62) | (13.85) | (5.38) | (9.38) | |
EV/EBIT |
61.42 | 335.53 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.62 | 0.00 | 0.01 | |
Price to Operating Income |
61.36 | 330.10 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
19.67 | 14.90 | 8.56 | 9.34 | |
Average Payables |
13.27 | 9.18 | 7.57 | 8.47 | |
Average Inventory |
16.97 | 14.04 | 15.33 | 9.40 | |
Average Assets |
108.74 | 90.87 | 84.12 | 70.18 | |
Average Common Equity |
35.27 | 27.53 | 25.29 | 19.55 |
Columns are period end dates